Ellington Management Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ellington Management Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-16,800	Closed	-$128K	–	403
2018 Q3	$128K	Buy	+16,800	New	+$113K	0.03%	469
2017 Q3	–	Sell	-34,600	Closed	-$192K	–	636
2017 Q2	$192K	Buy	+34,600	New	+$211K	0.03%	541
2017 Q1	–	Sell	-17,400	Closed	-$110K	–	690
2016 Q4	$110K	Buy	+17,400	New	+$90.5K	0.02%	496
2015 Q3	–	Sell	-11,719	Closed	-$175K	–	709
2015 Q2	$175K	Buy	+11,719	New	+$133K	0.04%	610
2015 Q1	–	Sell	-18,300	Closed	-$223K	–	677
2014 Q4	$223K	Buy	+18,300	New	+$202K	0.07%	416
2014 Q2	–	Sell	-32,500	Closed	-$344K	–	451
2014 Q1	$344K	Buy	+32,500	New	+$346K	0.1%	313

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Ellington Management Group's BCRX Position: Q4 2018 in Review

Ellington Management Group sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2018, closing a stake of 16,800 shares — an estimated $128K sold.

Ellington Management Group first reported a position in BCRX in Q1 2014 and held it in 6 quarters. The position peaked at $344K in Q1 2014. 123 funds tracked by Wall St. Rank hold BCRX as of Q4 2018.

Ellington Management Group reported no remaining BioCryst Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Ellington Management Group sold 16,800 BioCryst Pharmaceuticals shares in Q4 2018, an estimated $128K.
Ellington Management Group first reported a position in BioCryst Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Ellington Management Group's BioCryst Pharmaceuticals position peaked at $344K in Q1 2014.
123 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2018.

Based on Ellington Management Group's 13F filing for Q4 2018, filed 14 Feb 2019.